Clear.bio Raises $1.7M for Personalized Diabetes Care

Clear.bio, an Amsterdam-based healthtech startup, has successfully raised $1,700,000 in investment capital. The company, founded in 2019, is dedicated to helping individuals with type 2 diabetes manage their condition and improve their health through a data-driven approach, leveraging modern technology and scientific insights into nutrition. Clear.bio's core offering is a digital self-help tool designed to provide personalized dietary guidance. Recognizing that individuals react differently to food, their platform enables users to monitor real-time blood sugar levels via a sensor. By logging food and drink intake in the accompanying app, users receive immediate feedback on how their body processes specific nutrients, leading to data-driven, personalized nutritional advice. This empowers users to make informed choices, make small, smart dietary adjustments, and improve their blood sugar and overall health, often with support from dietitians via the app, potentially reducing reliance on medication. This newly secured funding underscores investor confidence in Clear.bio's innovative solution and its mission to transform diabetes management. The capital injection is planned to accelerate the company's growth initiatives, including further developing its platform capabilities and expanding its reach to more individuals seeking personalized health solutions. Having established itself as an official healthcare provider, Clear.bio has already assisted thousands in achieving healthier outcomes. The investment comes from a group of backers that includes Antler, Healthy.Capital, Future Food Fund, MSM, Achmea Innovation Fund, and Horizon Flevoland. Clear.bio aims to continue its trajectory of empowering people with type 2 diabetes to achieve significant health improvements through precise, data-backed nutritional interventions, furthering its mission to promote healthier lives.